CLAIMS

1. The use of benzydamine or the physiologically acceptable acid addition salts thereof in the manufacture of a medicament for the treatment of an inflammatory disease, wherein said inflammatory disease is selected from the group consisting of Crohn's disease, psoriatic arthritis, and psoriasis.

2. The use according to claim 1, wherein said medicament is formulated for systemic or topical administration.

3. The use according to claim 2, wherein said medicament for systemic administration comprises an amount of from 1 mg to 100 mg of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

4. The use according to claim 3, wherein said medicament for systemic administration comprises an amount of from 5 mg to 50 mg of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

5. The use according to claim 2, wherein said medicament for topical administration comprises an amount of from 1% to 20% by weight of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base, based on the total weight of the medicament.

6. The use according to claim 5, wherein said medicament for topical administration comprises an amount of from 1% to 10% by weight of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base, based on the total weight of the medicament.

7. The use of a pharmaceutical composition in the manufacture of a medicament for the treatment of an inflammatory disease by systemic or topical administration, wherein said inflammatory disease is selected from the group

consisting of Crohn’s disease, psoriatic arthritis, and psoriasis wherein said pharmaceutical composition comprises benzydamine or the physiologically acceptable acid addition salts thereof.

8. The use of the pharmaceutical composition for systemic administration according to claim 7, wherein said pharmaceutical composition comprises an amount of from 1 mg to 100 mg, more preferably from 5 mg to 50 mg, of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

9. The use of the pharmaceutical composition for topical administration according to claim 7, wherein said pharmaceutical composition comprises of from 1% to 20%, more preferably from 1% to 10%, by weight of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base, based on the total weight of the composition.